Methodist Children's Hospital of South Texas — San Antonio, Texas

Methodist Children's Hospital of South Texas is a clinical research site located in San Antonio, Texas, United States 78229-3993.

Crixeo Clinical Trials Trust Score: 92/100 (GOOD). This profile has not yet been claimed by the site owner.

Methodist Children's Hospital of South Texas has participated in 195 clinical trials with 67 currently active.

Therapeutic areas: Lymphoma, B Acute Lymphoblastic Leukemia, COVID-19 Infection.

Sponsors: Children's Oncology Group, National Cancer Institute (NCI), PedAL BCU, LLC.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in San Antonio

Browse all research sites in Texas · View every site in San Antonio

Sponsor Feasibility Report

Trust Score: 92/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Methodist Children's Hospital of South Texas?

Methodist Children's Hospital of South Texas has a Crixeo Trust Score of 92/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Methodist Children's Hospital of South Texas conducted?

Methodist Children's Hospital of South Texas has 195 clinical trials on record, with 67 currently active. Their work covers Lymphoma, B Acute Lymphoblastic Leukemia, COVID-19 Infection.

Is Methodist Children's Hospital of South Texas accredited by Crixeo Clinical Trials?

Methodist Children's Hospital of South Texas has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Methodist Children's Hospital of South Texas?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.